News Image

Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults

Provided By ACCESS Newswire

Last update: Mar 31, 2025

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19.

"We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna. "This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians vulnerable to RSV in the future."

RSV is a highly contagious respiratory virus that causes a substantial burden of disease, particularly in older adults. In the 2024 Australian winter period, RSV laboratory-notified cases in adults aged 65 and older were nearly two-thirds the number of influenza cases in the same age group.2 90% of RSV-related deaths reported nationally occurred in those aged 60 years and older, underscoring its potential for severe impact on older Australians.2

The approval is based on positive data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries.

About mRESVIA (Respiratory Syncytial Virus Vaccine)

mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes.

To date, Moderna has received marketing authorizations for its RSV vaccine in the United States, the European Union, Canada, Qatar, the United Arab Emirates, Taiwan, and the United Kingdom and has submitted regulatory applications in other markets worldwide.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Australian Therapeutic Goods Administration (TGA) granting approval for mRESVIA® (mRNA-1345); the potential for mRESVIA to reduce disease burden from RSV; and Moderna's pending marketing authorization applications for mRNA-1345. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna Contacts

International Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.Mirceawillats@modernatx.com

Australia Media:
Jemimah Brennan
Director, Communications & Corporate Affairs, Australia
jemimah.brennan@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

References

  1. Australian Register of Therapeutic Goods (ARTG) Information - https://www.tga.gov.au/resources/artg/411450

  2. Australian Respiratory Surveillance Report 11 - 29 July to 11 August 2024, https://www.health.gov.au/resources/publications/australian-respiratory-surveillance-report-11-12-august-to-25-august-2024 accessed 7 March 2025.

SOURCE: Moderna, Inc.



View the original press release on ACCESS Newswire

MODERNA INC

NASDAQ:MRNA (5/22/2025, 8:26:46 PM)

After market: 26.7595 +0.04 (+0.15%)

26.72

+0.92 (+3.57%)



Find more stocks in the Stock Screener

MRNA Latest News and Analysis

ChartMill News Image6 hours ago - ChartmillTop S&P500 movers in Thursday's session

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.

Mentions: TPL HUM MDT WSM ...

ChartMill News Image2 days ago - ChartmillWhat's going on in today's session: S&P500 movers

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.

Mentions: NEM INCY REGN HUM ...

ChartMill News Image2 days ago - ChartmillStay informed about the most active stocks in the S&P500 index on Tuesday's session.

Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for the market.

Mentions: F PFE UNH SMCI ...

ChartMill News Image2 days ago - ChartmillExploring the top movers within the S&P500 index during today's session.

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.

Mentions: HUM CPRT ES HSIC ...

ChartMill News Image3 days ago - ChartmillWhat's going on in today's session: S&P500 movers

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.

Mentions: BIIB GILD HUM UNH ...

ChartMill News Image3 days ago - ChartmillUncover the latest developments among S&P500 stocks in today's session.

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Monday as we examine the latest happenings in today's session.

Mentions: FCX TPL GILD HUM ...

ChartMill News Image6 days ago - ChartmillDiscover which S&P500 stocks are making waves on Friday.

Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Mentions: HSY LLY CI HUM ...

ChartMill News Image6 days ago - ChartmillExplore the top gainers and losers within the S&P500 index in today's session.

Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.

Mentions: FCX ALB HSY LLY ...

ChartMill News Image8 days ago - ChartmillStay informed with the top movers within the S&P500 index on Wednesday.

Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.

Mentions: IP TECH BMY DAL ...

ChartMill News Image8 days ago - ChartmillWhat's going on in today's session: S&P500 movers

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.

Mentions: LULU TECH WST CMG ...

ChartMill News Image15 days ago - ChartmillTop gainers and losers in the S&P500 index during Wednesday's after-hours session.

Discover the top S&P500 movers in Wednesday's after-hours session and stay informed about the post-market dynamics.

Mentions: PRU TECH BMY LLY ...

ChartMill News Image16 days ago - ChartmillMarket Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)

Wall Street Retreats as Pharma Stocks Tumble and Trade Uncertainty Lingers

Mentions: F MAT GILD PFE ...

Follow ChartMill for more